Xenon Pharmaceuticals (XENE) Other Non-Current Assets (2013 - 2026)

Xenon Pharmaceuticals (XENE) has 10 years of Other Non-Current Assets data on file, last reported at $8.3 million in Q1 2026.

• On a quarterly basis, Other Non-Current Assets rose 3.13% year-over-year to $8.3 million in Q1 2026; TTM through Mar 2026 was $8.3 million, a 3.13% increase from a year earlier, with the FY2025 full-year figure at $7.2 million, down 4.6% from the prior year.
• Other Non-Current Assets for Q1 2026 stood at $8.3 million, up from $7.2 million in the prior quarter.
• Over the last five years, Other Non-Current Assets for XENE reached as high as $9.2 million in Q2 2025 and fell as low as $7.1 million in Q3 2025.
• Historically, Other Non-Current Assets has averaged $7.7 million across 5 years, with a median of $7.5 million in 2024.
• Across the five-year window, Other Non-Current Assets declined 8.2% in 2024 and rose 23.89% in 2025, its largest moves.
• Year by year, Other Non-Current Assets stood at $7.8 million in 2022, then decreased by 4.58% to $7.4 million in 2023, then advanced by 1.35% to $7.5 million in 2024, then slipped by 4.6% to $7.2 million in 2025, then rose by 16.14% to $8.3 million in 2026.
• Per Business Quant data, the three most recent Other Non-Current Assets figures were $8.3 million in Q1 2026, $7.2 million in Q4 2025, and $7.1 million in Q3 2025.